Abstract
Introduction Schizophrenia patients have higher rates of type 2 diabetes mellitus (T2DM) than population comparisons and, in conjunction with highly prevalent obesity and cardiovascular disease, this translates into a 20% reduced life expectancy (1). Unfortunately, despite arguably better outcomes in several psychiatric domains including symptoms, cognition and quality of life, the mortality gap for patients is not narrowing but may indeed be widening (2). Preferential use of second-generation antipsychotics (SGAs) as opposed to older (first-generation antipsychotics, FGAs) antipsychotics may account for the widening mortality gap (3). This is because research has confirmed a link between SGA use and development of T2DM and other metabolic complications (1). Conversely, very little evidence has accumulated that would support a connection between discontinuation of SGAs and diabetes resolution, although implications in the prevailing context would be important. Here, we describe three cases of diabetes onset with SGA treatment and confirmed resolution after switch to an FGA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
